{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:32:32Z","timestamp":1793431952181,"version":"4.5.0"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. J. Clin. Oncol."],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1093\/jjco\/hyv207","type":"journal-article","created":{"date-parts":[[2016,1,30]],"date-time":"2016-01-30T20:18:02Z","timestamp":1454185082000},"page":"291-298","source":"Crossref","is-referenced-by-count":117,"title":["Skin problems and EGFR-tyrosine kinase inhibitor"],"prefix":"10.1093","volume":"46","author":[{"given":"Toshiyuki","family":"Kozuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,1,29]]},"reference":[{"key":"2016032909143767000_46.4.291.1","doi-asserted-by":"publisher","DOI":"10.1586\/era.13.47"},{"key":"2016032909143767000_46.4.291.2","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31827aedef"},{"key":"2016032909143767000_46.4.291.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10629.x"},{"key":"2016032909143767000_46.4.291.4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0032"},{"key":"2016032909143767000_46.4.291.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2015.09.005"},{"key":"2016032909143767000_46.4.291.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.038"},{"key":"2016032909143767000_46.4.291.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1245"},{"key":"2016032909143767000_46.4.291.8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2818"},{"key":"2016032909143767000_46.4.291.9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji055"},{"key":"2016032909143767000_46.4.291.10","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.1167.11.3","article-title":"The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers","volume":"11","author":"Tokumo","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2016032909143767000_46.4.291.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"key":"2016032909143767000_46.4.291.12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099314"},{"key":"2016032909143767000_46.4.291.13","doi-asserted-by":"publisher","DOI":"10.1126\/science.7618084"},{"key":"2016032909143767000_46.4.291.14","first-page":"3639","article-title":"Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition","volume":"23","author":"Yano","year":"2003","journal-title":"Anticancer Res"},{"key":"2016032909143767000_46.4.291.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2610"},{"key":"2016032909143767000_46.4.291.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrg758"},{"key":"2016032909143767000_46.4.291.17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12249.x"},{"key":"2016032909143767000_46.4.291.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.110"},{"key":"2016032909143767000_46.4.291.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.03.100"},{"key":"2016032909143767000_46.4.291.20","first-page":"2478","article-title":"Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients","volume":"9","author":"Malik","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2016032909143767000_46.4.291.21","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12340759"},{"key":"2016032909143767000_46.4.291.22","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.17.4657"},{"key":"2016032909143767000_46.4.291.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63654-1"},{"key":"2016032909143767000_46.4.291.24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1242\/jcs.110.2.113","article-title":"EGF-R dependent regulation of keratinocyte survival","volume":"110","author":"Rodeck","year":"1997","journal-title":"J Cell Sci"},{"key":"2016032909143767000_46.4.291.25","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-04-0238"},{"key":"2016032909143767000_46.4.291.26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04226.x"},{"key":"2016032909143767000_46.4.291.27","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2001.01356.x"},{"key":"2016032909143767000_46.4.291.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2008.06.010"},{"key":"2016032909143767000_46.4.291.29","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1970"},{"key":"2016032909143767000_46.4.291.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2005.12.004"},{"key":"2016032909143767000_46.4.291.31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1036"},{"key":"2016032909143767000_46.4.291.32","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.8.2.129"},{"key":"2016032909143767000_46.4.291.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1928"},{"key":"2016032909143767000_46.4.291.34","first-page":"4995","article-title":"Predicting skin toxicity according to EGFR polymorphisms in patients with colorectal cancer receiving antibody against EGFR","volume":"33","author":"Saito","year":"2013","journal-title":"Anticancer Res"},{"key":"2016032909143767000_46.4.291.35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.1128"},{"key":"2016032909143767000_46.4.291.36","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.12.122"},{"key":"2016032909143767000_46.4.291.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909530"},{"key":"2016032909143767000_46.4.291.38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"2016032909143767000_46.4.291.39","first-page":"8041","article-title":"Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advanced lung adenocarcinoma (LA): WJOG 5108L","volume":"32","author":"Katakami","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"key":"2016032909143767000_46.4.291.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"2016032909143767000_46.4.291.41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.4694"},{"key":"2016032909143767000_46.4.291.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.07.003"},{"key":"2016032909143767000_46.4.291.43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70381-X"},{"key":"2016032909143767000_46.4.291.44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70184-X"},{"key":"2016032909143767000_46.4.291.45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"2016032909143767000_46.4.291.46","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12723"},{"key":"2016032909143767000_46.4.291.47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2806"},{"key":"2016032909143767000_46.4.291.48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70604-1"},{"key":"2016032909143767000_46.4.291.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.01.026"},{"key":"2016032909143767000_46.4.291.50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055128"},{"key":"2016032909143767000_46.4.291.51","first-page":"975","article-title":"The management of molecular-targeted cancer drug-induced skin toxicity: a report from consensus conference held with volunteer dermatologists and medical oncologists","volume":"30","author":"Kawashima","year":"2014","journal-title":"Rinsyo Iyaku"},{"key":"2016032909143767000_46.4.291.52","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0434-6"},{"key":"2016032909143767000_46.4.291.53","first-page":"195","article-title":"Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician","volume":"9","author":"Gutzmer","year":"2011","journal-title":"J der Deutschen Dermatol Gesellschaft"},{"key":"2016032909143767000_46.4.291.54","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3747\/co.v18i3.877","article-title":"Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer","volume":"18","author":"Hirsh","year":"2011","journal-title":"Curr Oncol"},{"key":"2016032909143767000_46.4.291.55","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1197-6"},{"key":"2016032909143767000_46.4.291.56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3747\/co.v16i1.361","article-title":"Management of skin rash during egfr-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations","volume":"16","author":"Melosky","year":"2009","journal-title":"Curr Oncol"},{"key":"2016032909143767000_46.4.291.57","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq387"},{"key":"2016032909143767000_46.4.291.58","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0055"},{"key":"2016032909143767000_46.4.291.59","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0082"},{"key":"2016032909143767000_46.4.291.60","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23621"},{"key":"2016032909143767000_46.4.291.61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.6987"},{"key":"2016032909143767000_46.4.291.62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.7828"},{"key":"2016032909143767000_46.4.291.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.03.019"},{"key":"2016032909143767000_46.4.291.64","doi-asserted-by":"crossref","unstructured":"Melosky B , Anderson H , Burkes RL et al . Pan Canadian Rash Trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic lung cancer. J Clin Oncol 2015; [Epub ahead of print].","DOI":"10.1200\/JCO.2015.62.3918"},{"key":"2016032909143767000_46.4.291.65","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1684\/ejd.2010.0806","article-title":"Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab\u2014a report of 29 patients","volume":"20","author":"Katzer","year":"2010","journal-title":"Eur J Dermatol"},{"key":"2016032909143767000_46.4.291.66","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/27.5.607"},{"key":"2016032909143767000_46.4.291.67","first-page":"443","article-title":"Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues","volume":"35","author":"Thong","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"2016032909143767000_46.4.291.68","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12543487"},{"key":"2016032909143767000_46.4.291.69","first-page":"259","article-title":"Evaluation of tetracycline in the neutrophil chemotactic response","volume":"90","author":"Majeski","year":"1977","journal-title":"J Lab Clin Med"},{"key":"2016032909143767000_46.4.291.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.004"},{"key":"2016032909143767000_46.4.291.71","doi-asserted-by":"publisher","DOI":"10.1016\/0162-3109(95)00041-0"},{"key":"2016032909143767000_46.4.291.72","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80396-9"},{"key":"2016032909143767000_46.4.291.73","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70050-1"},{"key":"2016032909143767000_46.4.291.74","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700202"},{"key":"2016032909143767000_46.4.291.75","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ec1729"},{"key":"2016032909143767000_46.4.291.76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06835.x"},{"key":"2016032909143767000_46.4.291.77","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0330"},{"key":"2016032909143767000_46.4.291.78","first-page":"41","article-title":"Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids","volume":"4","author":"Bikowski","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"2016032909143767000_46.4.291.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.06.046"},{"key":"2016032909143767000_46.4.291.80","doi-asserted-by":"publisher","DOI":"10.2482\/haigan.54.978"},{"key":"2016032909143767000_46.4.291.81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0545"},{"key":"2016032909143767000_46.4.291.82","doi-asserted-by":"publisher","DOI":"10.2478\/v10019-008-0022-4"},{"key":"2016032909143767000_46.4.291.83","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000203385.45163.76"},{"key":"2016032909143767000_46.4.291.84","doi-asserted-by":"publisher","DOI":"10.1159\/000329914"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/46\/4\/291\/7195695\/hyv207.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T13:52:35Z","timestamp":1692193955000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article-lookup\/doi\/10.1093\/jjco\/hyv207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,29]]},"references-count":84,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,3,29]]},"published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1093\/jjco\/hyv207"],"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyv207","relation":{},"ISSN":["0368-2811","1465-3621"],"issn-type":[{"value":"0368-2811","type":"print"},{"value":"1465-3621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,29]]}}}